Interim Results From A New Trial Of CANCIDAS (caspofungin Acetate) In Pediatric Patients With Documented Fungal Infections
CANCIDAS (caspofungin acetate), given once daily, was evaluated as a treatment for patients 3 months to 17 years of age with documented or suspected fungal infections. The use of CANCIDAS in pediatric patients is investigational. [click link for full article]
More: continued here
Filed under: Infectious Diseases / Bacteria / Viruses on October 7th, 2007